ATE531367T1 - Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung - Google Patents

Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung

Info

Publication number
ATE531367T1
ATE531367T1 AT05813951T AT05813951T ATE531367T1 AT E531367 T1 ATE531367 T1 AT E531367T1 AT 05813951 T AT05813951 T AT 05813951T AT 05813951 T AT05813951 T AT 05813951T AT E531367 T1 ATE531367 T1 AT E531367T1
Authority
AT
Austria
Prior art keywords
compositions
compounds
methods
synuklein
poisoning
Prior art date
Application number
AT05813951T
Other languages
English (en)
Inventor
Susan Lindquist
Tiago Outeiro
Richard Labaudiniere
Original Assignee
Whitehead Biomedical Inst
Foldrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Foldrx Pharmaceuticals Inc filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE531367T1 publication Critical patent/ATE531367T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05813951T 2004-09-17 2005-09-16 Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung ATE531367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61079604P 2004-09-17 2004-09-17
PCT/US2005/033050 WO2006034003A2 (en) 2004-09-17 2005-09-16 Compounds, compositions and methods of inhibiting a-synuclein toxicity

Publications (1)

Publication Number Publication Date
ATE531367T1 true ATE531367T1 (de) 2011-11-15

Family

ID=36090510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05813951T ATE531367T1 (de) 2004-09-17 2005-09-16 Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung

Country Status (13)

Country Link
US (1) US8440705B2 (de)
EP (2) EP2433634A3 (de)
JP (1) JP5001843B2 (de)
CN (2) CN101060839A (de)
AT (1) ATE531367T1 (de)
AU (1) AU2005287137B2 (de)
BR (1) BRPI0515549A (de)
CA (1) CA2580767A1 (de)
ES (1) ES2376108T3 (de)
NO (1) NO20071860L (de)
NZ (4) NZ584773A (de)
WO (1) WO2006034003A2 (de)
ZA (1) ZA200703110B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640454A1 (en) * 2006-01-26 2007-08-09 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
BRPI0712268A2 (pt) * 2006-05-24 2012-01-17 Nagasaki University composição para diagnóstico de doença relacionada à amilóide
WO2008025152A1 (en) * 2006-08-28 2008-03-06 Mcmaster University Antibacterial agents
KR20120112548A (ko) * 2009-12-16 2012-10-11 뉴로포레 테라피스, 인코포레이티드 시누클레인 병을 치료하는데 적합한 화합물
ES2550939T3 (es) 2010-07-16 2015-11-13 Nivalis Therapeutics, Inc. Nuevos compuestos de dihidropiridin-2-(1H)-ona como inhibidores de la S-nitrosoglutatión reductasa y antagonistas del receptor de la neurocinina-3
US20130158035A1 (en) * 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US9815845B2 (en) 2010-10-13 2017-11-14 Trustees Of Boston University Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
CN103347520A (zh) * 2010-10-13 2013-10-09 波士顿大学管理委员会 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂
US9802948B2 (en) 2010-10-13 2017-10-31 Trustees Of Boston Univeristy Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
CN103906751A (zh) * 2011-10-02 2014-07-02 波士顿大学董事会 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
HK1220233A1 (zh) 2013-03-15 2017-04-28 怀特黑德生物医学研究院 用於神经变性疾病的细胞性发现平台
EP2970177A1 (de) 2013-03-15 2016-01-20 Pfizer Inc. Indolverbindungen zur ampk-aktivierung
CA2954978A1 (en) * 2014-07-29 2016-02-04 Institut Pasteur De Lille 2-oxo-3,4-dihydropyridine-5-carboxylates and their use
EP3191578B1 (de) 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Zellen zur expression von apolipoprotein e und verwendungen davon
GB201509663D0 (en) * 2015-06-03 2015-07-15 Johnson Matthey Plc Benzo(h)quinoline ligands and complexes thereof
WO2017176981A1 (en) 2016-04-08 2017-10-12 Baylor College Of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof
EP3600331A4 (de) 2017-03-27 2022-03-09 The Regents of the University of Colorado, A Body Corporate Kleinmolekülige inhibitoren von bakterieneffluxpumpen und verfahren zur verwendung derselben
WO2019074898A1 (en) * 2017-10-09 2019-04-18 Alsatech, Inc. DISAGGREGATION OF ALPHA-SYNUCLEIN WITH SMALL MOLECULES
IL280539B2 (en) * 2018-08-02 2024-08-01 Univ Boston Late sv40 factor (lsf) inhibitors
KR20210134065A (ko) * 2019-03-28 2021-11-08 주식회사 퍼스트바이오테라퓨틱스 벤조티아졸 화합물의 약제학적 염, 다형체 및 이들의 제조 방법
US11242353B2 (en) 2020-01-24 2022-02-08 Trustees Of Boston University Heterocyclic LSF inhibitors and their uses
CN112062770A (zh) * 2020-08-21 2020-12-11 台州学院 一种稠环二氢吡啶酮的制备方法
US11458132B2 (en) 2020-09-01 2022-10-04 Trustees Of Boston University Quinolin-2(1H)-one inhibitors of Late SV40 Factor
EP4638427A1 (de) * 2022-12-22 2025-10-29 Université Côte d'Azur Amidinoharnstoffderivate und ihre verwendung zur behandlung von krebs

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US610796A (en) 1898-09-13 Bicycle air-brake
GB158076A (de)
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE757938A (fr) 1969-10-23 1971-04-23 Bayer Ag Nouveaux benzothiazylamides d'acides cyclopropane- carboxylique, leur procede de preparation et leur application comme herbicides
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
JPS5516149B2 (de) * 1972-01-14 1980-04-30
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2418913A1 (de) 1974-04-19 1975-10-30 Sueddeutsche Kalkstickstoff Verfahren zur herstellung von 2-benzthiazolylguanidin
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5308857A (en) 1988-08-15 1994-05-03 Fujisawa Pharmaceutical Co., Ltd. Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
IT1228293B (it) 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
IL95548A0 (en) 1989-09-15 1991-06-30 Fujisawa Pharmaceutical Co Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
JP2000508339A (ja) 1996-10-01 2000-07-04 シーマ・ラブス・インコーポレイテッド 味隠蔽マイクロカプセル組成物及び製造方法
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
HUP0001232A3 (en) 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
AR011164A1 (es) 1997-02-28 2000-08-02 Lilly Co Eli Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o su sintesismediante el uso de dichos compuestos
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6506782B1 (en) 1998-02-27 2003-01-14 Athena Neurosciences, Inc. Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
AU2001265656A1 (en) 2000-06-05 2001-12-17 Johnny Easmon Heterocyclic hydrazones for use as anti-cancer agents
AU7887501A (en) 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
US7045290B2 (en) 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
JP2005516967A (ja) 2002-01-18 2005-06-09 ザ ジェネティクス カンパニー インコーポレーティッド β−セクレターゼインヒビター
US7183276B2 (en) * 2002-02-28 2007-02-27 Takeda Pharmaceutical Company Limited Azole compounds
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
CA2522497A1 (en) 2003-04-16 2004-11-04 Whitehead Institute For Biomedical Research Yeast ectopically expressing abnormally processed proteins and uses therefor
EP1667983A4 (de) * 2003-09-23 2010-07-21 Merck Sharp & Dohme Pyrazolmodulatoren von metabotropen glutamatrezeptoren
CA2640454A1 (en) * 2006-01-26 2007-08-09 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
JP4876867B2 (ja) * 2006-11-27 2012-02-15 株式会社Ｉｈｉ ターボ圧縮機のロータ

Also Published As

Publication number Publication date
NO20071860L (no) 2007-06-05
EP2433634A2 (de) 2012-03-28
CN101060839A (zh) 2007-10-24
JP5001843B2 (ja) 2012-08-15
EP1802303B1 (de) 2011-11-02
NZ584773A (en) 2012-07-27
CN102379872A (zh) 2012-03-21
HK1105893A1 (en) 2008-02-29
NZ588432A (en) 2012-03-30
US20080261953A1 (en) 2008-10-23
ES2376108T3 (es) 2012-03-09
WO2006034003A3 (en) 2006-07-13
EP1802303A2 (de) 2007-07-04
NZ588431A (en) 2012-02-24
EP1802303A4 (de) 2009-12-16
WO2006034003A2 (en) 2006-03-30
EP2433634A3 (de) 2012-07-18
AU2005287137B2 (en) 2012-03-22
CA2580767A1 (en) 2006-03-30
BRPI0515549A (pt) 2008-07-29
NZ554545A (en) 2010-10-29
US8440705B2 (en) 2013-05-14
AU2005287137A1 (en) 2006-03-30
JP2008513471A (ja) 2008-05-01
ZA200703110B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
ATE531367T1 (de) Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
EP1854415A4 (de) Chirurgische behandlungsvorrichtung
DK2324871T4 (da) Citratantikoaguleringssystem til ekstrakorporale blodbehandlinger
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE112005002742A5 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen
EP1991274A4 (de) Verfahren zur behandlung, prophylaxe und diagnose von knochenerkrankungen
NO20076241L (no) Terapier for vaskulaere sykdommer
DE602006002982D1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
NO20076405L (no) Anvendelse av 24-nor-UDCA
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
CY1114811T1 (el) Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων
DK2022786T3 (da) Middel mod mund- og klovsyge-virus til dyr, der hører til familien suidae eller får, og fremgangsmåde til forebyggelse eller behandling af mund- og klovsyge hos dyr, der hører til familien suidae eller får
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
EP1876900A4 (de) Phosphoinositid-modulation zur behandlung von alzheimer-krankheit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
IL185653A (en) Antibodies that call for the 1-kim salt region
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder